Cardiff Oncology, Inc. ( (CRDF) ) has released its Q1 earnings. Here is a breakdown of the information Cardiff Oncology, Inc. presented to its investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Cardiff Oncology, Inc. is a clinical-stage biotechnology company focused on developing novel cancer therapies through PLK1 inhibition, with its lead asset being onvansertib, a PLK1 inhibitor. In its latest earnings report for the first quarter of 2025, Cardiff Oncology reported a net loss of $13.4 million, an increase from the $10.0 million loss in the same period of 2024. The company’s revenue decreased to $0.1 million from $0.2 million, primarily from royalty revenues. Research and development expenses rose significantly to $10.5 million due to increased clinical trial activities, while selling, general, and administrative expenses also saw an increase to $4.0 million. Despite the losses, Cardiff Oncology maintains a cash position of $79.9 million, which is expected to fund operations into the first quarter of 2027. Looking ahead, Cardiff Oncology plans to continue advancing its clinical trials, particularly focusing on its lead candidate, onvansertib, in various cancer indications.